1-3 of 3
Danielle Hammond
Close
Sort by
Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2695–2706.
https://doi.org/10.1182/bloodadvances.2024012565
Published: 2024
Includes: Supplemental data
Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical Trials & Observations
Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2378–2387.
https://doi.org/10.1182/bloodadvances.2022008378
Published: 2023
Includes: Supplemental data
Journal Articles

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Chong Chyn Chua, Danielle Hammond, Andrew Kent, Ing Soo Tiong, Marina Y. Konopleva, Daniel A. Pollyea, Courtney D. DiNardo, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2022) 6 (13): 3879–3883.
https://doi.org/10.1182/bloodadvances.2022007083
Published: 2022
Includes: Supplemental data